Article
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2014
Heigener D F, Deppermann K M, Pawel J V, Fischer J R, Kortsik C, Bohnet S, Eiff M V, Koester W, Thomas M, Schnabel P A, Reck M
Abstract excerpt
BACKGROUND: Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotinib is non-inferior compared to chemotherapy as a first-line therapy in unselected elderly patients. MATERIALS AND METHODS: Patients ≥ 70 years with untreated,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.